Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Kumar

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
Leukemia|March 13, 2014
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myelomaW I Gonsalves, S V Rajkumar, V Gupta, et al.
International Journal of Impotence Research|March 12, 2016
Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscleB R Choi, S K Kumar, C Zhao, et al.
Leukemia|August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Leukemia|May 13, 2015
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapyM Alhaj Moustafa, S V Rajkumar, A Dispenzieri, et al.
International Journal of Impotence Research|October 9, 2015
Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscleB R Choi, S K Kumar, C Zhao, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
Leukemia|March 13, 2014
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myelomaW I Gonsalves, S V Rajkumar, V Gupta, et al.
International Journal of Impotence Research|March 12, 2016
Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscleB R Choi, S K Kumar, C Zhao, et al.
Leukemia|August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Leukemia|May 13, 2015
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapyM Alhaj Moustafa, S V Rajkumar, A Dispenzieri, et al.
International Journal of Impotence Research|October 9, 2015
Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscleB R Choi, S K Kumar, C Zhao, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Pageof 12